Rankings
▼
Calendar
URGN
UroGen Pharma Ltd.
$917M
FY 2013 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$3M
Net Income
-$3M
EPS (Diluted)
$-1.56
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$541,000
Balance Sheet
Total Assets
$3M
Total Liabilities
$484,000
Stockholders' Equity
$3M
Cash & Equivalents
$3M
← FY 2014
All Quarters
URGN FY 2013 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
